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Abstract
Background: Despite the increasing economic assessment of biomarker-guided therapies, no clear agreement
exists whether existing methods are sufficient or whether different methods might produce different cost-
effectiveness results. This study aims to examine current practices of modeling companion biomarkers when
assessing the cost-effectiveness of targeted cancer therapies. It investigates the current methods in modeling the
characteristics of companion diagnostics based on existing economic evaluations of biomarker-guided therapies in
cancer.
Methods: A literature search was performed using Medline, Embase, EconLit, Cochrane library for economic
evaluations of biomarker-guided therapies with companion diagnostics in cancer. Preferred Reporting Items of
Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. Studies were selected using pre-
specified eligibility criteria based on the PICO framework. To make the included studies more comparable, we
qualitatively synthesized the data under nine domains of methods where consensus was deemed lacking.
Results: Only four of the twenty-two studies included in this review were found to be of good quality with respect
to incorporating the characteristics of companion biomarkers in economic evaluations. However, many evaluations
focused on a pre-selected patient group rather than including all patients regardless of their biomarker status.
Companion biomarker characteristics captured in evaluations were often limited to the cost or the accuracy of the
test. Often, only the costs of biomarker testing were modelled. Clinical outcomes and health state utilities were
often not included due to the limited data generated by clinical trials. Methods of economic evaluation were not
applied consistently in assessments of companion cancer biomarkers for targeted therapies. It was also shown that
conflicting cost-effectiveness results were likely depending on what comparator arm was chosen and what
comparison structure was designed in the model.
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Conclusion: We found no consistent approach applied in assessing the value of companion biomarker tests and
including the characteristics of biomarkers in an economic evaluation of targeted oncology therapies. Currently,
many economic evaluations fail to capture the full value of companion biomarkers beyond sensitivity/specificity
and cost related to biomarker testing.
Keywords: Biomarker, Companion biomarker, Companion diagnostic, Precision medicine, Targeted therapy,
Oncology, Cancer, Economic evaluation, Health economics, Cost-effectiveness, Systematic review
Introduction
Economic evaluations (EEs) are increasingly used to in-
form decisions regarding market access, reimbursement
and coverage of new medical technologies including bio-
marker diagnostics for targeted therapies. Companion
biomarkers are used to select and guide the best treat-
ment options for patients prior to administering a corre-
sponding therapy. However, no agreement exists
whether existing methods are sufficient to evaluate the
health economic impact of biomarkers, or whether dif-
ferent methodological approaches might produce con-
flicting results concerning the cost-effectiveness of
biomarker-guided therapies.
This study focuses on companion biomarker tests for
targeted cancer therapies (i.e. companion diagnostics for
guided therapies in cancer). Specific biomarkers, known
as companion diagnostics (CDx) are the focus of this re-
view. CDx can be defined as a medical device (often
in vitro) providing information regarding the safe and ef-
fective use of a corresponding intervention [1]. CDx is
the diagnostic test labelled to be used prior to the ad-
ministration of a particular therapeutic product and
thus, the treatment decision is made based on the bio-
marker testing result. That is, the use of a specific test is
obligatorily proceeded by the provision of corresponding
therapy (e.g. HER2 testing prior to trastuzumab). If test
accuracy is not satisfactory, the treatment decision can
be detrimental to the patient outcomes when treated
with the biomarker-guided therapy.
Given the indirect impact of companion diagnostics
on the cost-effectiveness of biomarker-guided therapies,
the EEs of test-guided therapies need to incorporate not
only the characteristics of a medicine but also those of a
test. In other words, for a companion test to achieve the
improvement of patient health outcomes, the test must
result in a change in the administration of its subsequent
therapy. By influencing on the choice of a subsequent
therapy, the companion test can indirectly improve
health outcomes by delivering the right treatment to the
right patient. It can then lead to the improved treatment
effect of the corresponding guided therapy. Therefore,
the EEs of the biomarker-guided therapy should capture
the full spectrum of the co-dependency of the medicine
that interacts with the companion biomarker test that
assists in determining the right patient groups. However,
there seems to be no agreement existent in the EE ap-
proaches for this type of co-dependent technologies.
Consequently, few countries provided health EE
methods guide specific to the co-dependent technologies
such as companion diagnostics for biomarker-guided
therapies [2, 3].
This study aims to investigate current practices of
modeling and incorporating the characteristics of com-
panion biomarker tests when assessing the cost-
effectiveness of biomarker-guided therapies. It analyses
the approaches currently adopted in EEs and highlights
the current challenges and issues to be overcome to
reach a consensus on methods and data requirements
for EEs of companion diagnostics for biomarker-guided
therapies.
Methods
A systematic review of health economic evaluations of
companion diagnostics for targeted cancer therapies was
undertaken. This review was conducted following the
recommendations of the Preferred Reporting Items of
Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines [4, 5].
Literature search
A systematic literature search for EEs of cancer bio-
markers co-licensed to administer targeted therapies
(hereafter, called “companion biomarkers”) was con-
ducted using Medline (Ovid), Embase (Ovid), EconLit,
Cochrane library. A hand search of article citations and
review articles identified a further four articles [6–9].
The electronic search was performed using Medical
subject heading (MeSH) terms and keywords that were
developed for disease (cancer), intervention (companion
biomarkers for targeted therapies), and study design
(economic evaluations). These were combined with free-
word text searches using relevant economic terms (e.g.
“cost-effectiveness”) and the names of biomarker-guided
therapeutic products both in brand and generic terms.
The CDx approved by the US.
Food and Drug Administration (FDA) [10] were
targeted in the literature search. Studies published in
English were searched from 2014 to February 2021. The
7-year search period was chosen given that this literature
review aimed to explore current EE practice and to
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critically appraise them in depth. Seven years were con-
sidered to be long enough to capture a sufficient number
of recently published EEs and also to exclude any ap-
proaches not applicable to current practice. Search terms
are provided (Additional file 1).
Study selection
Studies were selected using prespecified inclusion and
exclusion criteria (Table 1) based on the PICOS
(Population, Intervention, Comparator, Outcome, Study
design) framework. Given the aims of this literature re-
view, studies failing to report important information
relevant to EEs of a companion biomarker test (e.g. bio-
marker characteristics, biomarker-related modeling in-
puts) were excluded.
The study selection had three stages. First, the articles
identified from the electronic databases were imported
into EndNote® and duplicate citations removed. Second,
the title and abstracts of the identified articles were
screened to assess suitability by the first reviewer (MKS)
and the studies clearly indicated as irrelevant were ex-
cluded. However,any studies with ambiguity were dis-
cussed with the second reviewer (JC). Third, the
remaining articles that met the inclusion criteria were
read in full text by the first reviewer (MKS) and cross-
checked by the second reviewer (JC). Disagreements at
any stage were resolved by discussion between the two
reviewers (MKS, JC).
Data analysis and synthesis
This review of current practice with respect to the EE of
companion biomarkers focuses on nine methodological
areas. These key areas were formulated based on previ-
ous studies and existing HTA documentation guides on
co-dependent technologies [2, 3, 11–15], the Consoli-
dated Health Economic Evaluation Reporting Standards
(CHEERS) checklist [16]. We first used the framework
of the CHEERS checklist and it provided useful informa-
tion in formulating the key method areas for this review
such as target population, study perspective, compara-
tors, preference-based outcomes, and estimating re-
source use and costs. However, the CHEERS checklist
alone was not sufficient to encompass the full spectrum
of the characteristics of companion diagnostics for
biomarker-guided therapies. Therefore, other informa-
tion found in existing studies [13, 14, 17] and govern-
mental documents [2, 3] was adopted in order to reflect
the indirect impact of companion biomarker tests on pa-
tient health outcomes. For example, evidence on the
measurement of the differential impact of the diagnostic
on patient health outcomes needed to be considered.
Thus, the EEs should incorporate the evidence of the
test’s performance (or diagnostic accuracy) that result in
TABLE 1 PICOS AND INCLUSION/EXCLUSION CRITERIA
PICOS Inclusion criteria Exclusion criteria







No predictive biomarkers for targeted therapies.
No biomarker-guided therapies.
Drugs without assessing companion biomarkers.
Universal screening tools.
Triage procedures.
Severity or progression analyses.













election of papers followed the eligibility criteria below:
Population: Patients with cancer tested with companion biomarker diagnostics for targeted therapies. Studies conducted on pre-specified patients with a
particular biomarker status were excluded if they did not consider any of CDx-related characteristics in their evaluations
Intervention: companion biomarkers for targeted anti-cancer therapies. These biomarkers are used as diagnostic tools to guide the optimal treatment option(s)
for patients responsive or unresponsive to the corresponding therapeutic products. Biomarker tests without market authorizations co-licensed with companion
therapeutic products were not of interest in this review
Comparator: conventional treatments (e.g. chemotherapy, best supportive care) or targeted therapies with or without the use of companion biomarker tests
Outcome: Methodological or modelling approaches, biomarker characteristics, data inputs of biomarker tests. Studies without sufficient information reported on
these items (e.g. abstracts) were excluded
Study type: economic evaluations including model or trial-based analyses
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a change in the management of subsequent therapeutic
service. Also, it was observed from our previous empir-
ical studies that the structure of comparing alternative
strategies and choosing comparator strategy in EEs
might lead to different cost-effectiveness results of their
corresponding test-guided therapies and health out-
comes [14, 15, 18].
The nine domains framed for the synthesis of this re-
view are following: (i) target population; (ii) study perspec-
tive; (iii) structure of comparing alternative strategies; (vi)
measurement of clinical value of companion biomarkers;
(v) measurement and valuation of preference-based out-
comes of companion biomarker tests; (vi) estimating re-
source use and costs; (vii) timing of the test use; (viii)
uncertainty analysis; (ix) data sources for biomarker-
related data inputs. The narrative syntheses and analyses
were performed.
for these ninemethodological areas. To be more spe-
cific, a list of questions was developed based on these
items (Additional file 2).
Results
We initially identified 2544 potential studies. After re-
moving duplicates and reviewing titles and abstracts,
100 publications were included for full-text screening.
78 papers were found to be not eligible for inclusion
according to pre-defiined inclusion/exclusion criteria
(Table 1). A considerable number of publications
(n = 21) had to be excluded because they did not
consider any characteristics of companion biomarker
tests in their EEs of test-guided therapies. Finally,
twenty-two papers found to be relevant and included
in this review. Details are provided in PRISMA dia-
gram (Additional file 3).
Characteristics of the included studies are detailed in
Table 2. Fig-
ure 1 provides the synthesized overview of whether the
key methodological areas were addressed or not in the
evaluations. The model inputs that were most frequently
missing, related to companion biomarker tests, were
preference-based outcomes, clinical utility, resource use,
and the timing of the test. A detailed analysis of the key
methodological areas by publication is provided in
additional file 4.
The most frequently used modeling type was a Markov
model (thirteen papers), followed by partitioned survival
model (three papers) and semi-Markov model (two pa-
pers). All economic evaluations were performed from a
third-party payer perspective except for two studies
which took a societal perspective and one study done on
both perspectives. All studies were performed for high-
income countries except for five studies of China and
one of Philippines.
Target population
The patient population targeted in EEs of biomarker-
guided therapies was varied, but fall into two broad
categories; patients with a known biomarker status, and
patients whose biomarker status is initially unknown.
Fourteen studies were performed on a pre-defined group
of patients with particular biomarker status [20–22, 24–
30, 32, 35–37]; however, they considered at least one
characteristic of companion biomarker tests in their
evaluations. Many EEs were conducted using a pre-
specified patient group with particular confirmed bio-
marker status, and authors used this to justify excluding
some of the key characteristics of companion biomarker
testing from their evaluations.
Study perspective
The study perspective defines the scope of costs and
health benefits to be assessed in an EE. All included
studies clearly reported their perspective. A majority of
studies showed that EEs were performed applying the
third-party payer perspective. Only three studies stated
that they employed a societal perspective [25, 29, 37];
two from low-and-middle income countries and one
from a high income country. Meanwhile, two USA stud-
ies [22, 23] were found to be more appropriately de-
scribed as a third-party payer perspective (i.e. Medicare)
although authors stated that their studies were analysed
from the societal perspective.
Given the nature of multiple purposes of biomarker
testing application or use, and the indirect impact of
companion biomarker diagnostics on patient health ben-
efits, a third party payer perspective might not be suffi-
cient to capture all costs and benefits relevant to
companion biomarkers when identifying patients suit-
able for the corresponding therapy. However, only two
studies considered indirect costs such as travel fees and
absenteeism costs, together with the cost of adverse
events [29, 37]. However, this study did not consider any
biomarker-related indirect costs either. For example,
Schnell-Inderst and colleagues conducted a targeted re-
view and highlighted measuring the potential effect
modifiers such as the dependency of treatment effects
on contextual factors and learning curve [38].
The strategies compared
It is widely accepted that current practice with respect
to the target population is a relevant alteranative strategy
with which to compare [39, 40].
Five different types of comparison have been under-
taken in the literature evaluating the use of companion
biomarkers in order to guide treatment in cancer. Three
of these occur when all patients considered regardless of
their biomarker status, and two types of comparison
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have been made when the focus is on patients with a
specific biomarker status (Fig. 2).
A total of eight studies featured involved test-treat
strategies, where those testing positive would receive the
guided therapy and those testing negative would receive
the non-guided therapy. Two studies [6, 41] compared
different test-treat strategies (Type 1). Three studies [6,
20, 23] compared a test-treat strategy with no testing
where all patients were treated with the guided therapy
(Type 2). Five studies [8, 23, 33, 34, 42] compared a test-
treat strategy with no testing where all patients received
the non-guided therapy (Type 3).
Fifteen studies considered patients with a specific
biomarker status. Eight studies [21, 24, 26, 27, 29, 30,
36, 37] involved the comparison of two (or more)
different guided therapies (Type 4). Eight studies [19,
20, 22, 25, 28, 30, 32, 35] compared patients receiving
a guided therapy with treatment with a non-guided
therapy (Type 5). Except for Huxley et al. [30], all of
these studies only considered one characteristic of the
companion biomarker test (usually the cost of
testing). The details are prevented in Fig. 2 and
Additional file 5.
Measuring the clinical value of companion biomarkers
No consensus currently exists on data requirements
when incorporating the clinical value of biomarkers into
the modeling of EEs of biomarker-guided therapies. For
example, the Diagnostic Assessment Programme re-
quires consideration of the diagnostic accuracy in the
appraisal of diagnostic tests [43], although it is not al-
ways feasible in practice especially when assessors are
not presented with any data on test accuracy. On the
other hand, the NICE methods guide for technology ap-
praisal does not necessarily require test accuracy but re-
quires inclusion of the associated costs of biomarker
testing [39]. Furthermore, none of the EEs reviewed
examined the accuracy of a companion biomarker diag-
nostic test separately, for example by testing different
cut-off thresholds including false positive and false nega-
tive results as part of uncertainty analysis. The cut-off
threshold is the cut-off point defining the presence of
the biomarker, determining biomarker-positive and
biomarker-negative patients for the administration of
corresponding co-dependent therapeutic agents [44–46].
Varying levels of accuracy may lead to different patient
subgroups being eligible for the corresponding drugs.
Fig. 1 Graph of including the characteristics of companion biomarkers in economic evaluation
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According to previous studies [13, 47], the clinical
value of biomarker tests could be assessed in three
ways; analytic validity, clinical validity, and clinical
utility. Analytic validity concerns how well a test de-
tects the presence or absence of a particular marker
[40]. Clinical validity refers to the performance of a
test (diagnostic accuracy) in detecting the presence of
a specific disorder; so-called sensitivity and specificity
[13]. Clinical utility is defined in the ACCE (analytical
validity, clinical validity, clinical utility, and ethical/
legal/social implications) model project as “how likely
the test is to significantly improve patient outcomes”,
which goes beyond sensitivity and specificity and then
which may change treatment options for the patient
[48]. In other words, clinical utility (effectiveness) of
companion testing technology is based on the ability
to improve patient health outcomes by altering treat-
ment decisions [49, 50].
Relatively few EEs considered the diagnostic accuracy
of biomarker testing using data on sensitivity and speci-
ficity [8, 33, 34, 41]. Many EEs did not consider the per-
formance of biomarker testing or often did not mention
this at all [6, 19–27, 29, 32, 37]. Otherwise, some studies
provided some assumptions or justifications why they
did not consider the clinical value of a companion diag-
nostic test [28, 30, 35, 36, 42]. It is often assumed that
the technical accuracy of patient stratification by bio-
marker testing is perfect and thus, the sensitivity and
specificity were either not considered or assumed to be
100%. However, no studies explicitly considered or as-
sumed the clinical utility of companion biomarkers in
their EEs. For example, no studies stated that the clinical
value of companion biomarker testing was supposedly
incorporated into the clinical effectiveness of the corre-
sponding drug based on the clinical trial of the sub-
population delineated by the diagnostic.
Fig. 2 STRATEGIES IN EES OF COMPANION BIOMARKER THERAPIES
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Meanwhile, a handful of studies considered the fre-
quency or prevalence of a particular biomarker status
among their target patient populations [6, 8, 23, 25, 26,
30, 32, 34, 41, 42]. Among them, only one study consid-
ered the probability of an unknown test result in the
analysis [41].
Measurement and valuation of preference-based
outcomes
The quality-adjusted life-year (QALY) is a preference-
based health outcome widely used in EEs of therapeutic
products [51, 52]. It is widely accepted because it allows
comparisons of health benefits and costs across different
disease areas and therapeutic interventions. However,
challenges emerge with the economic assessment of
companion biomarkers given the nature of targeted ther-
apies guided by companion biomarker testing and indir-
ect impact of companion biomarker testing on patient
outcomes. The current metrics for measuring
preference-based outcomes using population-based pref-
erences cannot fully capture patient preferences for bio-
marker tests [53]. There seem to be more aspects of
individual patient preference when valuing biomarker
tests for guided therapies rather than conventional non-
guided drugs. For example, patients could be informed
in advance of the likelihood of therapeutic response or
unresponsiveness prior to the provision of treatment.
Patients can have an improved sense of controlling
their own choices of therapeutic options informed by
their biomarker status rather than left with uncertainty
on whether to have the treatment or not. Shared deci-
sion making (SDM) and communication between pa-
tients and clinicians will put patients at the centre of
treatment decisions guided by companion biomarker test
results. Patients may feel empowered to make informed
decisions about their own treatment and care [54–56].
Although the provision of biomarker-guided therapy is
dictated by the patient’s biomarker status, being in-
formed of the biomarker status can support the SDM of
both clinicians and patients to explore more fully the po-
tential benefits and risks. It can then potentially improve
patient satisfaction with health services.
Companion diagnostics for cancer patients usually re-
quire collecting a bio-sample for analysis, with potential
implications for process utility (including reassurance or
information) [57–59]. Brennan and Dixon [60] report
different approaches being used to detect and measure
process utility such as gamble techniques, time trade-off,
and conjoint analysis. Some biomarker tests involve rela-
tively invasive methods to collect the bio-sample, such
as tissue biopsy, needle biopsy, skin biopsy in diagnosing
cancer [61, 62], that can be measured and incorporated
into QALY estimates. Yet, how to measure and incorp-
orate process utility into cost-utility analyses needs to be
further researched with more empirical studies in HTA.
If companion biomarker tests were already integrated
into the clinical study of measuring patient-reported
outcomes (PROs) for co-dependent therapeutic agents, it
can be assumed that the disutility or utility value of
companion biomarker testing is already embedded or in-
directly expressed in PROs of the corresponding therapy.
Yet, this aspect should be transparently reported in
health economic models of companion biomarkers or
biomarker-guided therapies. Nevertheless, none of the
EEs included in this systematic review discussed these
aspects of companion biomarker testing or indicated
how preference-based outcomes of companion bio-
marker devices were measured and valued. For example,
no studies explicitly included utility or disutility values
for biomarker testing. Where biomarker testing uses tis-
sues collected in a previous biopsy, it can be argued that
patient preferences do not need to be considered in eco-
nomic modeling. However, none of the EEs mentioned
this aspect or attempted to justify the omission of
preference-based outcomes of biomarker testing. As an
example, patients might need to undergo another biopsy
for the purpose of biomarker testing after cancer has
progressed to metastasis, or a second biopsy might be
needed to confirm the biomarker status when the testing
accuracy was unsatisfactory,or the turnaround time for
the biomarker testing may lead to additional waiting
time for patients to access the treatment,or patients
might experience anxiety or hopelessness when in-
formed that the test predicts non-response to the tar-
geted therapy and no alternative therapy options are
available.
Estimating resource use and costs
All included EE studies considered the costs of bio-
marker testing; however, some details were absent. Some
papers did not report the cost of biomarker testing de-
vices [19, 20, 25] and often a lump sum cost was mod-
elled without providing details on how the total cost
calculated [21, 22, 24, 32, 36, 37]. Several studies re-
ported at least some details regarding the data source or
the names/types of biomarker testing kits [6, 7, 23, 26–
30, 33–35, 42], but many EEs did not consider or report
the resource use parameters relevant to the testing of
companion biomarkers. None of the studies considered
the capital cost related to the initial purchase of a bio-
marker test kit or diagnostic equipment as well as other
costs such as training staff, relevant consumables, or lab
reporting tools. Even in the situation where laboratories
can re-purpose existing testing platforms to deliver the
new test, relevant costs of consumables and staff with
appropriate skills need to be considered. As an ex-
ample, the NICE committee was aware that ALK test-
ing would be not carried out in this specific clinical
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setting if crizotinib was not available [63], and there-
fore it is highly likely that hospitals would need to
purchase testing equipment, however, this was not
considered in the EE.
Timing of the test use
Details of where in the clinical pathway testing was
undertaken were often not reported. Only two studies
[6, 41] provided some explanation on this aspect; how-
ever, it was not clear how the timing of the test use was
considered in the analysis of the Westwood study [64].
Whereas Saito and colleagues [6] provided and justified
their assumptions. Given the nature of companion bio-
markers, the patient’s health benefit arises from the cor-
responding therapy guided by the testing result, which is
best understood as part of the clinical pathway in rela-
tion to its indirect impact on patient outcomes. There-
fore, companion biomarkers’ value is best assessed while
considering the timing of the test use; for example,
whether the testing was done at diagnosis or following
progression to metastasis. Westwood and colleagues [41]
noted that KRAS testing’s timing might vary; some clini-
cians might undertake routine testing for all patients at
diagnosis or some might wait until metastases have been
detected. Yet, they did not specify how their evaluation
was done in this respect.
Uncertainty analysis
Six studies [19, 28–30, 32–34] explored the impact of
cost-effectiveness of varying at least one component of
the characteristics of companion biomarker tests being
evaluated such as unit cost, total testing cost, test accur-
acy, cut-off thresholds, and biomarker prevalence.
However, many studies did not examine a test’s charac-
teristics separately from that of the corresponding ther-
apy. According to one HTA guideline, “if a diagnostic
test to establish the presence or absence of the bio-
marker is carried out solely to support the treatment de-
cision … a sensitivity analysis should be provided
without the cost of the diagnostic test” [39]. However,
out of four UK studies, two studies performed a sensitiv-
ity analysis on biomarker testing cost [28, 30].
Data sources for biomarker-related data inputs
All but three studies [19, 24, 32] provided data sources
used for biomarker tests’ characteristics. However, sev-
eral studies did not identify a specific companion bio-
marker testing kit, although some of them reported a
general biomarker testing type (e.g. RAS testing) and
therefore, several studies were not transparent and re-
producible. The most frequently used data sources were
previously published literature. However, testing cost in-
puts were mostly sourced from reimbursement sched-
ules [22, 23, 27, 28, 32, 42], manufactures or laboratories
[26, 37, 41], and if such information was unavailable, ex-
pert opinions were sought [30, 35].
Discussion
Altogether, twenty-two papers were included in this re-
view. One systematic review similar in terms of study
scope and objectivemainly focused on reviewing the sen-
sitivity and specificity of companion diagnostics and the
testing costs [12]. It did not provide a comprehensive re-
view of methodological approaches to EEs for assessing
the value for money of companion biomarkers in the
context of precision medicine. To the best of our know-
ledge, this is the first review providing a comprehensive
report on current practices and possible solutions in
terms of methodological approaches and evidence re-
quirements in assessing the value for money of compan-
ion biomarkers. Table 3 summaries possible solutions
and suggestions for the methodological issues identified
in this review.
Many of the EEs of biomarker-guided therapies focus
on a pre-selected patient group instead of including all
patients with a disease regardless of their biomarker sta-
tus. This is then often used as a justification for exclud-
ing companion biomarker testing from EE, leading to a
lack of robust economic evidence for the entire patient
group with the disease. It is important to consider all pa-
tients regardless of biomarker status and perform the
economic assessment of companion biomarker therapies
for all populations of interest with the condition or
disease.
Also, EEs need to be consistent with the decision
problem being addressed for targeted patient popula-
tions using a payer perspective. EEs usually adopt a per-
spective proposed in country-specific health technology
assessment guidelines and then, the third-party payer
perspective is the most frequently employed viewpoint
of analysis. However, considering the multiple purposes
of biomarker tests and the indirect health impact of
companion biomarkers on patient outcomes of corre-
sponding therapies, it might be better to adopt a holistic
viewpoint and capture the full spectrum of biomarkers’
health economic consequences. This would then permit
the inclusion of non-health-related costs and benefits
such as early information or reassurance on a treatment
option.
Applying the comparator strategy of relevance in spe-
cific clinical settings is crucial and may change the cost-
effectiveness outcomes of the intervention being
assessed. The economic evaluation of biomarker-guided
therapies often requires more than one comparator arm
such as biomarker-guided therapy without biomarker
testing and standard of care without biomarker testing
[17]. A previous study [14] sometimes found conflicting
cost-effectiveness results depending on the comparator
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TABLE 3 SUMMARY OF CURRENT PRACTICES AND SOLUTIONS IN ECONOMIC EVALUATIONS OF COMPANION BIOMARKERS
Methodological areas Issues identified in the current
practice of economic evaluations
Possible solutions/suggestions
Methodological approaches Data requirements
Target population Pre-selected population group with
known biomarker status was targeted
in EEs.
Target the entire patient group
including biomarker positive,
negative, and unknown.
Clinical data on all patients including
false positive, false negative, unknown
biomarker status.
Perspective Payer perspective was mostly used
following the HTA guidelines by the
reimbursement authority.
Holistic viewpoint desired (e.g.
societal perspective). However, if
infeasible, biomarker testing related
cost items should be included in
evaluations.
Cost data collected from
administrative database or real-world
setting.
Comparator With versus without the use of
biomarker testing compared in
evaluations yet in the context of the
same targeted therapy.
SOC in current routine clinical
practice should be employed as a
comparator in the context of treating
the disease condition of interest and
the target patient population.
Evidence on standard of care being
routinely practiced for the target
patient population with the disease
condition in a country-specific setting.
Comparison structure No consistency in structuring
strategies to be compared in
comparative analysis of companion
biomarkers for targeted therapies.
Test-treat versus treat-all with SOC is
suggested as a base-case comparison
structure.
Clinical data on patients treated all
with SOC without biomarker tested.
Clinical data on patients tested
negative.
Clinical effectiveness Clinical value of companion
biomarkers was limited to sensitivity/
specificity. Often, biomarker
prevalence data was ignored.
Sensitivity /specificity was often
assumed to be 100% or excluded
completely from the economic model
inputs.
Clinical value of companion
biomarkers beyond sensitivity
/specificity should be incorporated in
economic evaluations of biomarker-
guided therapies.
Clinical evidence generated from
clinical trials on both the drug and the
diagnostic. If possible, separate RCTs in
test positive and test negative patients
respectively treated with guided
therapy and non-guided therapy. In
addition, the clinical utility values in-
cluding the change of clinician’s be-
havior in choosing this treatment
option over SOC should be captured.
Preference-based
outcome
Utility and/or disutility values related
to biomarker testing were not
considered.
Biomarker related patient preferences
should be incorporated in economic
evaluations of biomarker-guided
therapies.
Individual patient utility (or disutility)
values on the use of a companion
biomarker test prior to the
administration of targeted therapy.
Patient preference data can be
acquired along the clinical trials,
reflecting all biomarker relevant
preference items.
Timing of the test use The timing of the use of companion
biomarker testing is often not
incorporated and not reported in
economic evaluations.
The value of companion biomarkers
should be understood throughout
the clinical pathways applicable to
the decision-making of clinicians.
The timing of the test use in clinical
routine settings is preferred over the
RCT setting.
Uncertainty analysis Many economic evaluations did not
examine the characteristics of a test
separately from that of the
corresponding therapy.
The characteristic components
relevant to a companion biomarker
diagnostic should be tested
separately as part of uncertainty
analysis of biomarker-guided therapy.
Value of information analysis can be
useful to inform the uncertainty
around current information/data
against perfect or partial perfect
information.
Information and model
inputs to be incorporated
in economic evaluations
of companion biomarkers
Limited number of model parameters
pertinent to biomarker testing was
incorporated into the economic
assessment of companion biomarkers.
Model inputs relevant to companion
biomarker testing should all be
captured and incorporated in
economic evaluations of biomarker-
guided therapies.
Name/type of biomarker testing
diagnostic/kit.
Resource use of testing.
Unit cost of testing.
Capital cost if the testing device is not
currently available in current clinical
settings.
Prevalence of biomarker status in
patient population.
Sensitivity/specificity.
Utility and/or disutility values of
performing the test in relation to
preference-based outcomes.
Clinical pathways including the test
(for example, when the test is
performed in routine clinical settings).
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strategy chosen such as test-treat versus treat-all with
the standard of care (SOC) and test-treat versus treat-all
with the new therapy. We found no consistency in the
choice of comparator strategies and in structuring the
strategies to be compared. Biomarker-guided therapies
were often evaluated by comparing biomarker testing
and no-testing strategies to administer the new interven-
tion. Such comparative analyses often ignore the stand-
ard of care being provided in current clinical practice.
These issues appear to be linked to one another. As
found in this study, many EEs of biomarker-guided ther-
apies do not necessarily consider the entire patient
population; it instead narrows down to a specific patient
group with known biomarker status. And this narrowed-
down population leads to a narrower scope of the deci-
sion problem being addressed by EEs, which may not be
necessarily congruent with the interest of decision-
makers (i.e. payers) for their reimbursement decision-
making of the entire patient group. Furthermore, this
narrowed-down scope of a decision problem and a pa-
tient population group appears to be used to justify the
inconsistent approaches in structuring the alternative
strategies and incorporating the characteristics of com-
panion tests in their EEs of biomarker-guided therapies.
For example, a considerable number of studies focused
on the population of biomarker-specified patients and
justified their comparative structure of ‘treat-all with
guided therapy’ versus ‘treat-all with non-guided therapy’
while incorporating only very limited data inputs related
to the companion diagnostics such as testing cost only.
Likewise, although the test’s performance (i.e. diagnostic
accuracy) is a key element of modeling companion diag-
nostics in EEs, the information for patients with false
negative and false positive results was often ignored or
blindly justified by the narrowed-scope of patient popu-
lations with known biomarker status. These lead to fur-
ther ignorance of key characteristics of companion
biomarker tests such as key epidemiological data like the
biomarker prevalence or mutation in the population
level.
Meanwhile, generating the evidence for improved
health outcomes is not always straightforward. If com-
panion biomarker tests are integrated into the clincal tri-
als of their guided therapies, then it can assume that
their clinical utility is already reflected in the clinical evi-
dence for the corresponding guided therapies [65].
Otherwise, it is not easy to show the clinical utility of
companion biomarkers in clinical practice. In other
words, the clinical utility of companion biomarker tests
is indirectly expressed in the patient outcome of their
co-dependent therapies. However, often, biomarker tests
are developed independently from the drug, and the
common practice of biomarker test developers in terms
of evidence generation is only limited to provide clinical
validity (i.e. sensitivity and specificity). Reflecting this
common practice in the generation of clinical evidence
for biomarkers, we found that assessing the clinical value
of companion biomarkers in EEs is limited to a consider-
ation of the sensitivity and specificity of the test.
Most studies considered and included the cost of com-
panion biomarker testing in their EEs. However, they
often did not provide sufficient details on how they cal-
culated the cost of testing and what data sources were
used. This posed challenges in terms of transparency
and reproducibility of EEs of companion biomarkers.
This may be because the testing cost is not standardized
(e.g. no coding systems exist for biomarker testing in
medical records) or not publicly available (e.g. secret pri-
cing or individually negotiated price at a hospital/labora-
tory level) in many countries. Given that no
standardized cost information such as unit costs is pub-
licly available, most economic evaluations might need to
rely on laboratory charges.
It is said, in the field of precision medicine, that we
need to introduce more flexible reimbursement systems
to reward innovation, reflecting the added value of diag-
nostics or biomarker tests [66]. Otherwise, the value of
biomarkers will not be fully captured and reflected in
EEs. This also leads to an issue of understanding the en-
tire clinical pathway in relation to the biomarker test
and capturing the added value of biomarkers along the
continuum of disease management and cure. Our study
showed that many evaluations failed to reflect this aspect
by not even reporting the timing of the test. Further-
more, the impact of companion biomarker tests in terms
of HRQoL or adverse events was largely ignored.
Conclusion
It is in the public interest to ensure timely integration of
new technologies into clinical use through adequate re-
imbursement and coverage levels. However, this requires
that test developers demonstrate robust evidence of the
health economic impact of biomarker tests. Companion
biomarker characteristics captured in EEs are often lim-
ited to the cost or the accuracy of the test. Often, only
the costs of biomarker testing are modelled. Clinical out-
comes or utilities are often difficult to include due to the
limited data generated by clinical trials.
We found that there was no consistent approach ap-
plied in assessing the value of biomarkers and including
the characteristics of biomarkers in an economic evalu-
ation of targeted oncology therapies. Currently, many
EEs fail to capture the full range of characteristics that
influence the value of companion biomarkers beyond
testing cost and sensitivity/specificity.
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